Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus
Nat Med. 2022;28(10):2124–2132 doi: 10.1038/s41591-022-02017-5
Data suggest that CD19 chimeric antigen receptor (CAR) T cell transfer is feasible, tolerable and highly effective in patients with SLE.
In this compassionate-use CAR T cell programme, Mackensen, et al. transduce autologous T cells from patients with SLE, with a lentiviral anti-CD19 CAR vector, expanded and reinfused. They show promising results with regards to deep depletion of B cells, improvement of clinical symptoms, and normalisation of laboratory parameters.